Potential for serotonergic agents to treat elevated intraocular pressure and glaucoma: focus on 5-HT2receptor agonists
| Autor: | Jesse A. May, Najam A. Sharif |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Agonist
Intraocular pressure genetic structures business.industry medicine.drug_class 5-HT2 receptor Biomedical Engineering Glaucoma Prostaglandin Ocular hypertension Pharmacology medicine.disease Serotonergic eye diseases Ophthalmology chemistry.chemical_compound chemistry medicine sense organs business Receptor Optometry |
| Zdroj: | Expert Review of Ophthalmology. 6:105-120 |
| ISSN: | 1746-9902 1746-9899 |
| DOI: | 10.1586/eop.10.69 |
| Popis: | Although several classes of drugs, including FP-receptor prostaglandin agonist analogs, are available to treat elevated intraocular pressure (IOP) associated with glaucoma, novel pharmaceuticals to treat this potentially blinding disease are still being sought. With recent demonstration of potent IOP-lowering activity of serotonin-2 receptor agonists in conscious ocular hypertensive Cynomolgus monkey eyes, the prospects of this unexampled class of compounds yielding new drugs for the treatment of elevated IOP look bright. This article reviews the ocular serotonergic literature pertaining to elevated IOP in patients with ocular hypertension and glaucoma, the data on ocular hypotensive serotonin-2 agonists, and discusses their potential mechanism(s) of action at the cellular and whole-animal level. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|